GlobeNewswire·Nov 9, 2026, 4:30 PM ET

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results

Updated interim data for bamzireotide navoxetan (VMT-α-NET) supports a therapeutic window & potential best-in-class profile in neuroendocrine tumors (NETs).
Cohort 4 of the VMT-α-NET dose-finding study closed recruitment on October 30, 2026, with 20 patients enrolled, while the meningioma cohort remains open.
Lapemelanotide zapixetar (VMT01) showed meaningful antitumor activity in metastatic melanoma, with 12 patients treated in the monotherapy cohort as of October 30, 2026.
PSV359 received FDA Fast Track Designation for FAP-positive solitary fibrous tumors in October 2026.
An agreement with Merck supports potential evaluation of PSV359 in combination with Keytruda (pembrolizumab) for certain lung & colorectal cancers.
Perspective Therapeutics reported approximately $202 million in cash & investments as of September 30, 2026, sufficient to fund operations into 2028.
The company targets an end-of-Phase 2 meeting with the FDA for VMT-α-NET in the first quarter of 2027.
Manufacturing construction at the Chicago metro site is expected to be completed in early 2027.
Research & development expenses were $26.1 million for the three months ended September 30, 2026, compared to $20.3 million in the same period of 2025.
Net loss for the quarter ended September 30, 2026, was $32.4 million, or $0.27 per share.